Feasibility and Preliminary Efficacy of combined home-based fecal calprotectin self-testing and therapeutic drug monitoring-guided intervention in Patients with moderate-to-severe inflammatory bowel disease.

IF 1.8 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

European Journal of Gastroenterology & Hepatology Pub Date : 2025-08-15 DOI:10.1097/MEG.0000000000003061

Guomin Lu, Jing Sun, Hu Du

{"title":"Feasibility and Preliminary Efficacy of combined home-based fecal calprotectin self-testing and therapeutic drug monitoring-guided intervention in Patients with moderate-to-severe inflammatory bowel disease.","authors":"Guomin Lu, Jing Sun, Hu Du","doi":"10.1097/MEG.0000000000003061","DOIUrl":null,"url":null,"abstract":"Background: Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, significantly impact patients' lives. Effective management often involves invasive and costly monitoring.Objective: To evaluate the feasibility of integrating home-based fecal calprotectin testing with therapeutic drug monitoring (TDM) in managing moderate-to-severe IBD.Methods: A prospective, single-arm pilot study involved patients performing weekly home-based fecal calprotectin tests and attending regular clinic visits for TDM. Data on adherence, clinical disease activity, fecal calprotectin levels, therapeutic adjustments, and healthcare utilization were collected and analyzed.Results: High adherence to home-based fecal calprotectin testing (88%) and strong concordance with laboratory-based fecal calprotectin measures were observed. Clinical disease activity scores significantly decreased from a baseline of 7.2-2.7 by week 24. The proportion of patients achieving clinical remission increased from 0% at baseline to 50% at week 24. TDM facilitated 28 therapeutic adjustments, including 20 dose escalations, five de-escalations, and three therapy switches.Conclusion: Integrating home-based fecal calprotectin testing with TDM is feasible for personalized management of IBD. The observed clinical trends warrant confirmation in controlled trials.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000003061","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, significantly impact patients' lives. Effective management often involves invasive and costly monitoring.

Objective: To evaluate the feasibility of integrating home-based fecal calprotectin testing with therapeutic drug monitoring (TDM) in managing moderate-to-severe IBD.

Methods: A prospective, single-arm pilot study involved patients performing weekly home-based fecal calprotectin tests and attending regular clinic visits for TDM. Data on adherence, clinical disease activity, fecal calprotectin levels, therapeutic adjustments, and healthcare utilization were collected and analyzed.

Results: High adherence to home-based fecal calprotectin testing (88%) and strong concordance with laboratory-based fecal calprotectin measures were observed. Clinical disease activity scores significantly decreased from a baseline of 7.2-2.7 by week 24. The proportion of patients achieving clinical remission increased from 0% at baseline to 50% at week 24. TDM facilitated 28 therapeutic adjustments, including 20 dose escalations, five de-escalations, and three therapy switches.

Conclusion: Integrating home-based fecal calprotectin testing with TDM is feasible for personalized management of IBD. The observed clinical trends warrant confirmation in controlled trials.

查看原文本刊更多论文

家中粪便钙保护蛋白自检与治疗药物监测联合干预中重度炎症性肠病患者的可行性及初步疗效

背景：炎症性肠病（IBD），包括克罗恩病和溃疡性结肠炎，严重影响患者的生活。有效的管理通常涉及侵入性和昂贵的监测。目的：探讨家庭粪便钙保护蛋白检测与治疗性药物监测（TDM）结合治疗中重度IBD的可行性。方法：一项前瞻性单臂先导研究涉及患者每周进行基于家庭的粪便钙保护蛋白测试，并定期就诊TDM。收集和分析依从性、临床疾病活动度、粪便钙保护蛋白水平、治疗调整和医疗保健利用的数据。结果：家庭粪便钙保护蛋白检测依从性高（88%），实验室粪便钙保护蛋白检测一致性强。到第24周，临床疾病活动性评分从7.2-2.7的基线显著下降。达到临床缓解的患者比例从基线时的0%增加到第24周时的50%。TDM促进了28次治疗调整，包括20次剂量升级，5次剂量降级和3次治疗切换。结论：将家庭粪便钙保护蛋白检测与TDM相结合，可实现IBD的个性化治疗。观察到的临床趋势值得在对照试验中得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Gastroenterology & Hepatology 医学-胃肠肝病学

CiteScore

4.40

自引率

4.80%

发文量

269

审稿时长

1 months

期刊介绍： European Journal of Gastroenterology & Hepatology publishes papers reporting original clinical and scientific research which are of a high standard and which contribute to the advancement of knowledge in the field of gastroenterology and hepatology. The journal publishes three types of manuscript: in-depth reviews (by invitation only), full papers and case reports. Manuscripts submitted to the journal will be accepted on the understanding that the author has not previously submitted the paper to another journal or had the material published elsewhere. Authors are asked to disclose any affiliations, including financial, consultant, or institutional associations, that might lead to bias or a conflict of interest.